FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023649317> ?p ?o ?g. }

• W2023649317 endingPage "209" @default.
• W2023649317 startingPage "207" @default.
• W2023649317 abstract "The population-based case–control study CECILE investigated the impact of various menopausal hormone therapy (MHT) products on breast cancer (BC) risk in 1,555 postmenopausal women [1]. The case group (n = 739) included incident cases of in situ (!) or invasive BC in postmenopausal women. The control group (n = 816) included women from the general population within predefined quotas by age and socio-economic status (SES). While quotas by age were applied to obtain similar distributions by age among controls and among cases, quotas by SES in control women were applied to reflect the distribution by SES of women in the general population in the study area. Data of participants were obtained by a structured questionnaire during in-person interviews, and from pathology reports if applicable, respectively. Women were divided into current and past MHT user. MHTs were classified in estrogen-only therapy (ET), estrogen combined with progestin therapy (EPT) and tibolone. EPT was subdivided in three subtypes according to the progestogen constituent: natural micronized progesterone, progesterone derivatives, and testosterone derivatives. In comparison to never MHT users, any current or past MHT use (ET, EPT, tibolone) was not associated with an increased BC risk. However, in subanalysis BC risk was significantly increased for current use of EPT for 4 or more years (n = 73 cases and n = 56 controls, adjusted OR 1.55; 95 % CI 1.02–2.36). Within the group of current EPT users for 4 or more years, 14 cases had used estrogens combined with micronized progesterone (n = 17 controls), and 55 a combination with a synthetic progestogen (n = 34 controls), respectively. Compared to never MHT use, current use of EPT containing a synthetic progestogen for 4 or more years was associated with a significantly increased BC risk (adjusted OR 2.07; 95 % CI 1.26–3.39), but EPT containing micronized progesterone was not (adjusted OR 0.79; 95 % CI 0.37–1.71). 73 % of current MHT users started treatment within the first year of onset of menopause. Early EPT (n = 52 cases and n = 38 controls, adjusted OR 1.65; 95 % CI 1.02–2.69), but not early ET, starters had a significantly higher BC risk compared to never MHT users. In contrast, MHT initiation beyond 1 year after menopause was not associated with an increased BC risk. The authors concluded that: (1) ET and EPT containing natural progesterone did not increase BC risk whereas, (2) BC risk was increased in users of tibolone or EPT containing a synthetic progestogen, respectively, and that (3) MHT use early after onset of menopause was associated with an increased BC risk as compared to women who delay MHT beyond 1 or more years." @default.
• W2023649317 created "2016-06-24" @default.
• W2023649317 creator A5012995116 @default.
• W2023649317 date "2014-05-20" @default.
• W2023649317 modified "2023-09-23" @default.
• W2023649317 title "Is breast cancer risk the same for all progestogens?" @default.
• W2023649317 cites W1502751121 @default.
• W2023649317 cites W1593442063 @default.
• W2023649317 cites W1966934872 @default.
• W2023649317 cites W1980394791 @default.
• W2023649317 cites W2039395322 @default.
• W2023649317 cites W2049413564 @default.
• W2023649317 cites W2051559140 @default.
• W2023649317 cites W2078593930 @default.
• W2023649317 cites W2104687197 @default.
• W2023649317 cites W2108143007 @default.
• W2023649317 cites W2112442316 @default.
• W2023649317 cites W2112457093 @default.
• W2023649317 cites W2119270722 @default.
• W2023649317 cites W2136339009 @default.
• W2023649317 cites W2140565809 @default.
• W2023649317 cites W2141358477 @default.
• W2023649317 cites W2144816499 @default.
• W2023649317 cites W4229914791 @default.
• W2023649317 doi "https://doi.org/10.1007/s00404-014-3270-0" @default.
• W2023649317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24838289" @default.
• W2023649317 hasPublicationYear "2014" @default.
• W2023649317 type Work @default.
• W2023649317 sameAs 2023649317 @default.
• W2023649317 citedByCount "4" @default.
• W2023649317 countsByYear W20236493172015 @default.
• W2023649317 countsByYear W20236493172018 @default.
• W2023649317 countsByYear W20236493172019 @default.
• W2023649317 countsByYear W20236493172020 @default.
• W2023649317 crossrefType "journal-article" @default.
• W2023649317 hasAuthorship W2023649317A5012995116 @default.
• W2023649317 hasBestOaLocation W20236493172 @default.
• W2023649317 hasConcept C121608353 @default.
• W2023649317 hasConcept C126322002 @default.
• W2023649317 hasConcept C131872663 @default.
• W2023649317 hasConcept C2776306185 @default.
• W2023649317 hasConcept C2776607906 @default.
• W2023649317 hasConcept C2777164284 @default.
• W2023649317 hasConcept C2777457466 @default.
• W2023649317 hasConcept C2779279991 @default.
• W2023649317 hasConcept C2780159708 @default.
• W2023649317 hasConcept C2780275930 @default.
• W2023649317 hasConcept C2780572241 @default.
• W2023649317 hasConcept C2908647359 @default.
• W2023649317 hasConcept C29456083 @default.
• W2023649317 hasConcept C530470458 @default.
• W2023649317 hasConcept C71924100 @default.
• W2023649317 hasConcept C99454951 @default.
• W2023649317 hasConceptScore W2023649317C121608353 @default.
• W2023649317 hasConceptScore W2023649317C126322002 @default.
• W2023649317 hasConceptScore W2023649317C131872663 @default.
• W2023649317 hasConceptScore W2023649317C2776306185 @default.
• W2023649317 hasConceptScore W2023649317C2776607906 @default.
• W2023649317 hasConceptScore W2023649317C2777164284 @default.
• W2023649317 hasConceptScore W2023649317C2777457466 @default.
• W2023649317 hasConceptScore W2023649317C2779279991 @default.
• W2023649317 hasConceptScore W2023649317C2780159708 @default.
• W2023649317 hasConceptScore W2023649317C2780275930 @default.
• W2023649317 hasConceptScore W2023649317C2780572241 @default.
• W2023649317 hasConceptScore W2023649317C2908647359 @default.
• W2023649317 hasConceptScore W2023649317C29456083 @default.
• W2023649317 hasConceptScore W2023649317C530470458 @default.
• W2023649317 hasConceptScore W2023649317C71924100 @default.
• W2023649317 hasConceptScore W2023649317C99454951 @default.
• W2023649317 hasIssue "2" @default.
• W2023649317 hasLocation W20236493171 @default.
• W2023649317 hasLocation W20236493172 @default.
• W2023649317 hasLocation W20236493173 @default.
• W2023649317 hasLocation W20236493174 @default.
• W2023649317 hasOpenAccess W2023649317 @default.
• W2023649317 hasPrimaryLocation W20236493171 @default.
• W2023649317 hasRelatedWork W1996813448 @default.
• W2023649317 hasRelatedWork W2020609352 @default.
• W2023649317 hasRelatedWork W2023649317 @default.
• W2023649317 hasRelatedWork W2026103499 @default.
• W2023649317 hasRelatedWork W2065061094 @default.
• W2023649317 hasRelatedWork W2078746766 @default.
• W2023649317 hasRelatedWork W2082663871 @default.
• W2023649317 hasRelatedWork W2417440471 @default.
• W2023649317 hasRelatedWork W2436802623 @default.
• W2023649317 hasRelatedWork W2123922341 @default.
• W2023649317 hasVolume "290" @default.
• W2023649317 isParatext "false" @default.
• W2023649317 isRetracted "false" @default.
• W2023649317 magId "2023649317" @default.
• W2023649317 workType "article" @default.